PV Audit Strategy Guide.
Pharmacovigilance audit strategy: how to build a compliant and effective framework.
A strong pharmacovigilance audit strategy is essential for maintaining compliance, protecting patient safety, and showing regulators that the PV system is being monitored in a structured and consistent way. In both the EU and the UK, marketing authorisation holders are expected to audit their pharmacovigilance systems regularly as part of their quality assurance responsibilities. That makes audit planning more than an administrative task. It is a core part of a well-functioning PV system.
One of the biggest challenges is gaining full visibility across the entire pharmacovigilance landscape. Companies often work with affiliates, vendors, service providers, regional teams, and partner organisations, all of which may play a role in PV activities. If even one critical process or third party is overlooked, the audit approach may be incomplete. That can create inspection risk, especially where there is no clear documented strategy, no formal risk-based assessment, or delays in audit reporting and follow-up actions.
An effective PV audit strategy should look beyond a short-term schedule. It needs to set out, at a high level, how audit activities will be managed over a longer period, typically several years. It should cover governance, risk management, internal controls, and all relevant PV processes, from case handling and signal management to aggregate reporting, training, CAPA management, documentation control, and interfaces with other departments such as regulatory affairs or medical information. It should also account for delegated and outsourced activities, including those performed by affiliates and external partners.
A useful starting point is the pharmacovigilance system master file. The PSMF can help map the wider audit universe by identifying the entities, activities, and responsibilities that make up the PV system. However, organisations should not assume the PSMF is automatically complete or fully reliable without review. It is important to check whether all service providers are captured, whether responsibilities are clearly defined, and whether critical elements such as the global safety database, QPPV responsibilities, and PSMF management itself are appropriately considered within the audit scope.
Once the audit universe has been defined, risk assessment becomes the foundation for prioritisation. Not every area carries the same level of risk, so organisations need a practical method for assessing likelihood, impact, and timing. This should consider risk to both the business and to patient safety. The outcome should be clearly documented, showing how risks were identified, how they were classified, and how they influenced audit planning. Without that traceability, it becomes difficult to justify why certain audits were prioritised and others deferred.
Management endorsement is another critical element. A compliant audit strategy should not sit in isolation within the QA function. Senior leadership, the responsible PV roles, and the QPPV should have visibility of the strategy and formally support it. This matters not only for governance, but also for ensuring the necessary budget, resourcing, and authority are in place to deliver the audit program effectively.
From the strategy flows the audit program, which translates long-term intent into a more detailed schedule of planned audits. This program should explain what will be audited, when, and why. Higher-risk areas should receive appropriate focus, but lower-risk activities should not be ignored entirely. Over time, the program should ensure full coverage of the PV system so that no critical area remains unaudited. Because business models, partnerships, and risk profiles change, the audit program should be treated as a living document, updated when new risks emerge or priorities shift, with changes properly documented and approved.
At the operational level, each audit should be supported by clear procedures and planning. This includes defining who will perform the audit, how it will be resourced, the scope and timelines, reporting expectations, and how outcomes will be communicated to relevant stakeholders, including the QPPV where applicable. Good documentation is essential throughout. Audit records, reports, and evidence of distribution should be maintained carefully, not only for internal control but also to demonstrate compliance during inspections.
Ultimately, a compliant pharmacovigilance audit strategy is about much more than scheduling audits. It is about creating a structured, risk-based, and well-documented framework that connects strategy, planning, execution, and oversight. When organisations invest the time to define their audit universe properly, align plans to risk, and maintain strong records, audits become more effective and inspection readiness becomes easier to sustain.
